Radiation plus immune therapy shows promise for Tough-to-Treat lymphoma
NCT ID NCT07528352
First seen Apr 25, 2026 · Last updated Jun 22, 2026 · Updated 14 times
Summary
This early-stage trial is testing whether giving radiation therapy before a bispecific antibody drug (either epcoritamab or glofitamab) is safe and feasible for people with relapsed or refractory diffuse large B-cell lymphoma. The study will enroll 12 adults who have already tried at least two prior treatments. The main goal is to see if this combination keeps serious side effects like cytokine release syndrome and neurological problems at acceptable levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huntsman Cancer Institute at University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Epcoritamab or Glofitamab (bispecific antibodies) plus external beam radiation therapy
What this could lead to
If successful, this combination could offer a new treatment option for patients with hard-to-treat diffuse large B-cell lymphoma who have run out of standard therapies.
What could go wrong
This is a very early, small Phase 1b trial with only 12 participants, so results may not apply broadly. The main risks are serious side effects like cytokine release syndrome and neurological toxicity.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.